Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.51 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.49 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.49 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.49 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | BRD4 | O60885 | 1/20 | 0.48 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.47 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.47 |
| ▸ | ITK | Q08881 | 2/20 | 0.46 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.45 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | XBP1 | P17861 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL562040 | 0.89 | NPC1 (0.45) | HSD11B1ADORA2ATAS1R3TAS1R1TAS1R2 | |
| SCHEMBL561692 | 0.83 | POLB (0.70) | TAS1R3TAS1R1TAS1R2POLBBRD4 | |
| SCHEMBL561920 | 0.83 | POLB (0.70) | TAS1R3TAS1R1TAS1R2POLBBRD4 | |
| SCHEMBL562053 | 0.82 | POLB (0.67) | TAS1R3TAS1R1TAS1R2POLBBRD4 | |
| SCHEMBL10722280 | 0.81 | HSD11B1 (0.70) | HSD11B1ADORA2ABRD4TSHRL3MBTL1 | |
| SCHEMBL562419 | 0.80 | POLB (0.65) | TAS1R3TAS1R1TAS1R2POLBBRD4 | |
| SCHEMBL10720234 | 0.78 | HSD11B1 (0.56) | HSD11B1BRD4ITKTSHRL3MBTL1 | |
| SCHEMBL561750 | 0.78 | TAS1R3 (0.49) | ADORA2ATAS1R3TAS1R1TAS1R2POLB | |
| SCHEMBL28148662 | 0.76 | HSD11B1 (0.55) | HSD11B1ADORA2ABRD4TSHRNPSR1 | |
| SCHEMBL1353088 | 0.76 | LMNA (0.65) | HSD11B1ADORA2ABRD4TSHRL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240300931-A1 | Composition and Methods for Treating Attention Deficit Disorders | LIPPA ARNOLD STAN (US) | 2024-09-12 | — | — | US | claimed |
| US-20240100023-A1 | Compositions and Methods For Treating Spinal Cord Injuries | LIPPA ARNOLD S (US) | 2024-03-28 | — | — | US | claimed |
| US-20230373982-A1 | Compositions And Methods For Treating Attention Deficit Disorders | LIPPA ARNOLD STAN (US) | 2023-11-23 | — | — | US | claimed |
| US-20230129330-A1 | Compositions And Methods For Treating Attention Deficit Disorders | LIPPA ARNOLD STAN (US) | 2023-04-27 | — | — | US | claimed |
| US-20210340130-A1 | Compositions and methods for treating attention deficit disorders | LIPPA ARNOLD STAN (US) | 2021-11-04 | — | — | US | claimed |
| US-20190112300-A1 | Compositions And Methods For Treating Attention Deficit Disorders | LIPPA ARNOLD STAN (US) | 2019-04-18 | — | — | US | claimed |
| EP-2154970-B1 | DI-SUBSTITUTED AMIDES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | RESPIRERX PHARMACEUTICALS INC (US) | 2017-10-25 | — | — | EP | claimed |
| US-8404682-B2 | Di-substituted amides for enhancing glutamatergic synaptic responses | CORTEX PHARMACEUTICALS, INC. (US) | 2013-03-26 | — | — | US | claimed |
| US-20120035173-A1 | DI-SUBSTITUTED AMIDES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | RESPIRERX PHARMACEUTICALS INC | 2012-02-09 | — | — | US | claimed |
| US-8013003-B2 | Di-substituted amides for enhancing glutamatergic synaptic responses | CORTEX PHARMACEUTICALS, INC. (US) | 2011-09-06 | — | — | US | claimed |
| US-20100120764-A1 | DI-SUBSTITUTED AMIDES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | RESPIRERX PHARMACEUTICALS INC | 2010-05-13 | — | — | US | claimed |
| US-20240355686-A1 | Clinical Methods and Pharmaceutical Compositions Employing AMPA Receptor Antagonists to Treat Glioblastoma and Other Cancers | RADIN DANIEL PIERCE (US) | 2024-10-24 | — | — | US | disclosed |
| US-20240300931-A1 | Composition and Methods for Treating Attention Deficit Disorders | LIPPA ARNOLD STAN (US) | 2024-09-12 | — | — | US | disclosed |
| US-20240100023-A1 | Compositions and Methods For Treating Spinal Cord Injuries | LIPPA ARNOLD S (US) | 2024-03-28 | — | — | US | disclosed |
| US-20230373982-A1 | Compositions And Methods For Treating Attention Deficit Disorders | LIPPA ARNOLD STAN (US) | 2023-11-23 | — | — | US | disclosed |
| US-8013003-B2 | Di-substituted amides for enhancing glutamatergic synaptic responses | CORTEX PHARMACEUTICALS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-20100120764-A1 | DI-SUBSTITUTED AMIDES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | RESPIRERX PHARMACEUTICALS INC | 2010-05-13 | — | — | US | disclosed |
| US-20100120764-A1 | DI-SUBSTITUTED AMIDES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | RESPIRERX PHARMACEUTICALS INC | 2010-05-13 | — | — | US | disclosed |
| US-20100120764-A1 | DI-SUBSTITUTED AMIDES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | RESPIRERX PHARMACEUTICALS INC | 2010-05-13 | — | — | US | disclosed |
| WO-2008143963-A1 | DI-SUBSTITUTED AMIDES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | CORTEX PHARMACEUTICALS, INC. (US) | 2008-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210340130-A1 | Compositions and methods for treating attention deficit disorders | GRIN2A, GRIN2C, GRM2 | HSD11B1 607/4885ADORA2A 112/4885TAS1R3 4030/4885 |
| US-20240100023-A1 | Compositions and Methods For Treating Spinal Cord Injuries | CHAT, NTRK2, GMFG | HSD11B1 1417/4885ADORA2A 225/4885TAS1R3 4607/4885 |
| US-20230129330-A1 | Compositions And Methods For Treating Attention Deficit Disorders | GRIN2A, GRIN2C, GRM2 | HSD11B1 607/4885ADORA2A 112/4885TAS1R3 4030/4885 |
| US-20120035173-A1 | DI-SUBSTITUTED AMIDES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | GRIN2A, GRIN2B, SLC18A2 | HSD11B1 1958/4885ADORA2A 110/4885TAS1R3 2246/4885 |
| US-20100120764-A1 | DI-SUBSTITUTED AMIDES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | DRD2, DRD3, GAP43 | HSD11B1 2056/4885ADORA2A 396/4885TAS1R3 2130/4885 |
| US-20230373982-A1 | Compositions And Methods For Treating Attention Deficit Disorders | GRIN2A, GRIN2C, GRM2 | HSD11B1 607/4885ADORA2A 112/4885TAS1R3 4030/4885 |
| US-20240300931-A1 | Composition and Methods for Treating Attention Deficit Disorders | GRIN2A, GRIN2C, NTRK2 | HSD11B1 537/4885ADORA2A 111/4885TAS1R3 4027/4885 |
| US-20190112300-A1 | Compositions And Methods For Treating Attention Deficit Disorders | GRIN2A, GRIN2C, GRM2 | HSD11B1 607/4885ADORA2A 112/4885TAS1R3 4030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.